Unknown

Dataset Information

0

Novel adenosine derivatives against SARS-CoV-2 RNA-dependent RNA polymerase: an in silico perspective.


ABSTRACT:

Background

SARS-CoV-2 is a newly emerged human coronavirus that severely affected human health and the economy. The viral RNA-dependent RNA polymerase (RdRp) is a crucial protein target to stop virus replication. The adenosine derivative, remdesivir, was authorized for emergency use 10 months ago by the United States FDA against COVID-19 despite its doubtful efficacy against SARS-CoV-2.

Methods

A dozen modifications based on remdesivir are tested against SARS-CoV-2 RdRp using combined molecular docking and dynamics simulation in this work.

Results

The results reveal a better binding affinity of 11 modifications compared to remdesivir. Compounds 8, 9, 10, and 11 show the best binding affinities against SARS-CoV-2 RdRp conformations gathered during 100 ns of the Molecular Dynamics Simulation (MDS) run (- 8.13 ± 0.45 kcal/mol, - 8.09 ± 0.67 kcal/mol, - 8.09 ± 0.64 kcal/mol, and - 8.07 ± 0.73 kcal/mol, respectively).

Conclusions

The present study suggests these four compounds as potential SARS-CoV-2 RdRp inhibitors, which need to be validated experimentally.

SUBMITTER: Sonousi A 

PROVIDER: S-EPMC8222949 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC10754943 | biostudies-literature
| S-EPMC7222627 | biostudies-literature
| S-EPMC7189410 | biostudies-literature
| S-EPMC9750507 | biostudies-literature
| S-EPMC8340315 | biostudies-literature
| S-EPMC8532373 | biostudies-literature
| S-EPMC8979119 | biostudies-literature
| S-EPMC7992627 | biostudies-literature
| S-EPMC7778578 | biostudies-literature
| S-EPMC9729590 | biostudies-literature